Composition and method of an orally administered antimicrobial peptide vectored in a bacterial expression vehicle

Patent metadata

Field	Value
Publication number	US-11814628-B2
Application number	US-202118008512-A
Country	US
Kind code	B2
Filing date	Jun 14, 2021
Priority date	Jun 18, 2020
Publication date	Nov 14, 2023
Grant date	Nov 14, 2023

Abstract

The inventive subject matter includes an antimicrobial peptide vectored composition made of a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules. More specifically these novel recombinant antimicrobial peptide effector molecules exhibit preferential anti-microbial activity. The utility of the current inventive subject matter has demonstrated a reduced viability of Eimeira acervulina sporozoites in vitro using a sporozoite killing assay. More specifically, the antimicrobial peptide vectored composition is a bacterial protein expression vehicle expressing one or more recombinant antimicrobial peptide effector molecules, wherein the one or more recombinant antimicrobial peptide effector molecules are engineered from a NK-lysin gene and the one or more recombinant antimicrobial peptide effector molecules are engineered to express functionally active NK-2.

First claim

What is claimed is:

1. A method to treat a subject in need of a treatment comprising:
orally administering a therapeutically effective amount of an antimicrobial peptide vectored composition comprising a bacterial protein expression vehicle comprised of a whole cell Bacillus subtilis transformed with a replicable plasmid DNA expression construct codon-optimized for expressing functionally active NK-2, wherein the subject is poultry and said poultry are in need of treatment for Avian coccidiosis, comprising the step of orally administering to the subject the therapeutically effective amount of the antimicrobial peptide vectored composition to induce cytotoxicity to treat an Avian coccidiosis infection.

2. The method of claim 1 , wherein the subject is poultry and said poultry are in need of treatment to increase body weight, comprising the step of orally administering to the subject the therapeutically amount of a stable strain of a probiotic B. subtilis expressing cNK-2 to increase body weight of said subject.

Assignees

• Us Biologic Inc
• Us Agriculture

Inventors

• Van Oosterwijk Jolieke Gerdy
• Richer Luciana Meirelles
• Zatechka Douglas Steven
• Kim Woohyun
• Lillehoj Hyun Soon
• Gray Cyril
• Przybyszewski Christopher Anthony

Classifications

• C12N15/75 Primary

  for Bacillus · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K35/742

  Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes · CPC title

• C07K14/465

  from birds · CPC title

• A61P33/02

  Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title